West Cancer Center Joins CancerLinQ® as Participating Practice

For immediate release
September 5, 2017


Julianne Lee

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that West Cancer Center in Tennessee has signed an agreement to participate in the CancerLinQ® platform. 

“The CancerLinQ® rapid learning system continues to be enriched through the participation of remarkable cancer care facilities such as West Cancer Center. West Cancer Center has a proud tradition of excellence propelled by a unique interdisciplinary team of scientists, researchers and care providers,” said CancerLinQ LLC CEO Kevin Fitzpatrick. “Participation in CancerLinQ® will support their delivery of high-quality care and will in turn greatly contribute to the larger cancer community.”

CancerLinQ® is a powerful platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines.

West Cancer Center delivers care to more than 30,000 patients each year as part of a partnership with Methodist Healthcare and the University of Tennessee Health Science Center, combining leaders in education, research, and medical care. The center has a long-standing commitment to providing patients access to clinical trials, which includes Phase I through Phase III studies. 

“We are extremely excited to be participating in CancerLinQ,” said Lee Schwartzberg, MD, FACP, Executive Director of West Cancer Center and Chief, Division of Hematology/Oncology at UTHSC. “The power of CancerLinQ will allow us to deliver even higher quality care to our patients, aid us in matching clinical and molecular data for treatments and clinical trials, and improve our operations.”

To date, 100 practices in 40 states and the District of Columbia, representing more than 1,500 oncologists, have signed agreements to participate in CancerLinQ®.

CancerLinQ® is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen®.

CancerLinQ® is a project of CancerLinQ LLC. For more information, please visit CancerLinQ.org.

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.